Arvinas

We are developing firstinclass protein degradation therapeutics to degrade & destroy diseasecausing proteins via the body's own protein disposal system.

Suggest edits

Raised

$175M

Follow us

Companies in the same industry

Alexa global traffic share

Twitter followers

Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2

People

Add info

Latest funding

$120,000,000

IPO - 2018

$55,000,000

Venture capital (Series C) - 2018

Canaan Partners RA Capital Management New Leaf Venture Partners +6

Team Size

1–10

Employees

I work here

Location

United States

Headquarters

Explore United States

Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug

Arvinas Stock Price Doubled Today: Why It Happened

Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance

$120,000,000 IPO

VC-backed Arvinas goes public

$55,000,000 Venture capital (Series C)

Index

By TNW

Arvinas

Arvinas

Overview

Funding 2

People

Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug

Arvinas Stock Price Doubled Today: Why It Happened

Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance

VC-backed Arvinas goes public

Arvinas Completes $55M Series C